Dare Bioscience, Inc. (DARE)

Over the past six months, Daré Bioscience's stock price has decreased by 44.34%. Key events impacting the stock include the Q3 2025 earnings report, grant funding from the Gates Foundation, commercialization plans for DARE to PLAY™ Sildenafil Cream and two vaginal probiotics, a positive interim DSMB outcome for the Ovaprene® Phase 3 study, and the Q2 2025 financial results.

Based on the available information, there is no explicit mention of demand seasonality for Daré Bioscience, Inc.'s products or services. The company focuses on developing and commercializing solutions for ongoing women's health needs, which are generally not subject to seasonal fluctuations in demand.

Daré Bioscience, Inc. is a biopharmaceutical company focused on advancing products for women's health within the Pharmaceuticals and Biotechnology sectors, with a primary focus on Drug Discovery and Pharmaceuticals. The company aims to develop differentiated therapies that prioritize women's health and well-being, expanding treatment options and improving outcomes across various areas such as contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health, and menopause. The company's product portfolio includes XACIATO™, Ovaprene®, Sildenafil Cream, 3.6%, DARE-HRT1, DARE-VVA1, DARE-CIN, DARE-PDM1, DARE-204 and DARE-214, DARE-FRT1 and DARE-PTB1, DARE-HPV, DARE-LARC1, DARE-LBT, DARE-GML, DARE-RH1, DARE-PTB2, and two Vaginal Probiotics.

Daré Bioscience, Inc. is headquartered in San Diego, California, United States. The company's primary market focus is the United States, where it is advancing its products through FDA regulatory pathways and commercialization efforts. Additionally, some of its grant-funded programs are aimed at addressing unmet global needs, especially in low- and middle-income country settings.

Daré Bioscience has maintained a positive brand reputation in the past year, particularly within the women's health and biopharmaceutical communities. Daré Bioscience leadership has been recognized on the "Medicine Maker's Power List" and "Endpoints News' Women in Biopharma." Sabrina Martucci Johnson was honored as one of "Fierce Pharma's Most Influential People in Biopharma" in 2023. The company placed #1 in the Small Company category of the San Diego Business Journal's 2023 Best Places to Work Awards. The extension of a strategic partnership with Premier Research and continued receipt of significant grant funding from organizations like the Gates Foundation further solidifies Daré's commitment to advancing its women's health portfolio.

Daré Bioscience, Inc. has a mixed ownership structure comprising institutional investors, insiders, and retail investors. Approximately 6.70% to 10.1% of the stock is owned by institutional investors, 7.89% is owned by insiders, and 84.77% is held by retail investors. Sabrina Martucci Johnson, the President and CEO, owns the most shares of Daré Bioscience, Inc.